{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T17:04:17Z","timestamp":1788368657086,"version":"build-2803163510"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2022,7,23]],"date-time":"2022-07-23T00:00:00Z","timestamp":1658534400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,7,23]],"date-time":"2022-07-23T00:00:00Z","timestamp":1658534400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP17ck0106336 and JP20ck0106614"],"award-info":[{"award-number":["JP17ck0106336 and JP20ck0106614"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"name":"National Cancer Center Research and Development Fund"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[2022,11,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>This randomised phase II\/III trial aimed to determine whether perioperative chemotherapy with gemcitabine plus docetaxel (GD) is non-inferior to the standard Adriamycin plus ifosfamide (AI) in terms of overall survival (OS) in patients with soft tissue sarcoma (STS).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Patients with localised high-risk STS in the extremities or trunk were randomised to receive AI or GD. The treatments were repeated for three preoperative and two postoperative courses. The primary endpoint was OS.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Among 143 enrolled patients who received AI (70 patients) compared to GD (73 patients), the estimated 3-year OS was 91.4% for AI and 79.2% for GD (hazard ratio 2.55, 95% confidence interval: 0.80\u20138.14,\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.78), exceeding the prespecified non-inferiority margin in the second interim analysis. The estimated 3-year progression-free survival was 79.1% for AI and 59.1% for GD. The most common Grade 3\u20134 adverse events in the preoperative period were neutropenia (88.4%), anaemia (49.3%), and febrile neutropenia (36.2%) for AI and neutropenia (79.5%) and febrile neutropenia (17.8%) for GD.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Although GD had relatively mild toxicity, the regimen\u2014as administered in this study\u2014should not be considered a standard treatment of perioperative chemotherapy for high-risk STS in the extremities and trunk.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Clinical trial registration<\/jats:title>\n                    <jats:p>jRCTs031180003.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1038\/s41416-022-01912-5","type":"journal-article","created":{"date-parts":[[2022,7,23]],"date-time":"2022-07-23T01:04:13Z","timestamp":1658538253000},"page":"1487-1496","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Perioperative Adriamycin plus ifosfamide vs. gemcitabine plus docetaxel for high-risk soft tissue sarcomas: randomised, phase II\/III study JCOG1306"],"prefix":"10.1038","volume":"127","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5138-8952","authenticated-orcid":false,"given":"Kazuhiro","family":"Tanaka","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryunosuke","family":"Machida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akira","family":"Kawai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Nakayama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Tsukushi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kunihiro","family":"Asanuma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshihiro","family":"Matsumoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroaki","family":"Hiraga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koji","family":"Hiraoka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Munenori","family":"Watanuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsukasa","family":"Yonemoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Abe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirohisa","family":"Katagiri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7511-6388","authenticated-orcid":false,"given":"Yoshihiro","family":"Nishida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akihito","family":"Nagano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiyuki","family":"Suehara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Kawashima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masanori","family":"Kawano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Morii","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Hatano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junya","family":"Toguchida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomotake","family":"Okuma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masanobu","family":"Takeyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Takenaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshihiro","family":"Akisue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taisuke","family":"Furuta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makoto","family":"Emori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toru","family":"Hiruma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidetatsu","family":"Outani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuji","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoko","family":"Kataoka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haruhiko","family":"Fukuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshifumi","family":"Ozaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukihide","family":"Iwamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,7,23]]},"reference":[{"key":"1912_CR1","unstructured":"WHO Classification of Tumours Editorial Board. WHO classification of tumours, soft tissue and bone tumours. Lyon: International Agency for Research on Cancer; 2020."},{"key":"1912_CR2","unstructured":"American Cancer Society. Cancer facts and figures 2022, soft tissue sarcoma. https:\/\/www.cancer.org\/cancer\/soft-tissue-sarcoma.html. 2022. Accessed 28 Apr 2022."},{"key":"1912_CR3","unstructured":"Japanese Orthopaedic Association Musculoskeletal Tumor Committee. Soft Tissue Tumor Registry in Japan 2019. Tokyo: National Cancer Centre; 2019."},{"key":"1912_CR4","unstructured":"National Comprehensive Cancer Network. Clinical Practice Guidelines in Oncology. Soft tissue sarcoma, version 1. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/sarcoma.pdf. 2022. Accessed 28 Apr 2022."},{"key":"1912_CR5","doi-asserted-by":"publisher","first-page":"1348","DOI":"10.1016\/j.annonc.2021.07.006","volume":"32","author":"A Gronchi","year":"2021","unstructured":"Gronchi A, Miah AB, Dei Tos AP, Abecassis N, Bajpai J, Bauer S, et al. Soft tissue and visceral sarcomas: ESMO-EURACAN-GENTURIS clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2021;32:1348\u201365.","journal-title":"Ann Oncol."},{"key":"1912_CR6","doi-asserted-by":"publisher","first-page":"1238","DOI":"10.1200\/JCO.2001.19.5.1238","volume":"19","author":"S Frustaci","year":"2001","unstructured":"Frustaci S, Gherlinzoni F, De Paoli A, Bonetti M, Azzarelli A, Comandone A, et al. Adjuvant chemotherapy for adult soft tissue sarcomas of the extremities and girdles: results of the Italian randomized cooperative trial. J Clin Oncol. 2001;19:1238\u201347.","journal-title":"J Clin Oncol."},{"key":"1912_CR7","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1016\/S1470-2045(12)70346-7","volume":"13","author":"PJ Woll","year":"2012","unstructured":"Woll PJ, Reichardt P, Le Cesne A, Bonvalot S, Azzarelli A, Hoekstra HJ, et al. Adjuvant chemotherapy with doxorubicin, ifosfamide, and lenograstim for resected soft-tissue sarcoma (EORTC 62931): a multicentre randomised controlled trial. Lancet Oncol. 2012;13:1045\u201354.","journal-title":"Lancet Oncol."},{"key":"1912_CR8","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1002\/cncr.23592","volume":"113","author":"N Pervaiz","year":"2008","unstructured":"Pervaiz N, Colterjohn N, Farrokhyar F, Tozer R, Figueredo A, Ghert M. A systematic meta-analysis of randomized controlled trials for adjuvant chemotherapy for localized resectable soft tissue sarcoma. Cancer. 2008;113:573\u201381.","journal-title":"Cancer"},{"key":"1912_CR9","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1200\/JCO.2011.37.7218","volume":"30","author":"A Gronchi","year":"2012","unstructured":"Gronchi A, Frustaci S, Mercuri M, Martin J, Lopez-Pousa A, Verderio P, et al. Short, full-dose adjuvant chemotherapy in high-risk adult soft tissue sarcomas: a randomized clinical trial from the Italian Sarcoma Group and the Spanish Sarcoma Group. J Clin Oncol. 2012;30:850\u20136.","journal-title":"J Clin Oncol."},{"key":"1912_CR10","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1093\/jjco\/hyu220","volume":"45","author":"K Tanaka","year":"2015","unstructured":"Tanaka K, Mizusawa J, Fukuda H, Araki N, Chuman H, Takahashi M, et al. Perioperative chemotherapy with ifosfamide and doxorubicin for high-grade soft tissue sarcomas in the extremities (JCOG0304). Jpn J Clin Oncol. 2015;45:555\u201361.","journal-title":"Jpn J Clin Oncol."},{"key":"1912_CR11","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-019-6114-2","volume":"19","author":"K Tanaka","year":"2019","unstructured":"Tanaka K, Mizusawa J, Naka N, Kawai A, Katagiri H, Hiruma T, et al. Ten-year follow-up results of perioperative chemotherapy with doxorubicin and ifosfamide for high-grade soft-tissue sarcoma of the extremities: Japan Clinical Oncology Group study JCOG0304. BMC Cancer. 2019;19:890.","journal-title":"BMC Cancer"},{"key":"1912_CR12","doi-asserted-by":"publisher","first-page":"2283","DOI":"10.1093\/annonc\/mdw430","volume":"27","author":"A Gronchi","year":"2016","unstructured":"Gronchi A, Stacchiotti S, Verderio P, Ferrari S, Martin Broto J, Lopez-Pousa A, et al. Short, full-dose adjuvant chemotherapy in high-risk adult soft tissue sarcomas: long-term follow-up of a randomized clinical trial from the Italian sarcoma group and the Spanish sarcoma group. Ann Oncol. 2016;27:2283\u20138.","journal-title":"Ann Oncol."},{"key":"1912_CR13","doi-asserted-by":"publisher","first-page":"2755","DOI":"10.1200\/JCO.2006.10.4117","volume":"25","author":"RG Maki","year":"2007","unstructured":"Maki RG, Wathen JK, Patel SR, Priebat DA, Okuno SH, Samuels, et al. Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: results of sarcoma alliance for research through collaboration study 002. J Clin Oncol. 2007;25:2755\u201363.","journal-title":"J Clin Oncol."},{"key":"1912_CR14","doi-asserted-by":"publisher","first-page":"1794","DOI":"10.1016\/j.ejca.2015.05.010","volume":"51","author":"EJ Davis","year":"2015","unstructured":"Davis EJ, Chugh R, Zhao L, Lucas DR, Biermann JS, Zalupski MM, et al. A randomised, open-label, phase II study of neo\/adjuvant doxorubicin and ifosfamide versus gemcitabine and docetaxel in patients with localised, high-risk, soft tissue sarcoma. Eur J Cancer. 2015;51:1794\u2013802.","journal-title":"Eur J Cancer"},{"key":"1912_CR15","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1093\/jjco\/hyu080","volume":"44","author":"K Kataoka","year":"2014","unstructured":"Kataoka K, Tanaka K, Mizusawa J, Kimura A, Hiraga H, Kawai A, et al. A randomized phase II\/III trial of perioperative chemotherapy with adriamycin plus ifosfamide versus gemcitabine plus docetaxel for high-grade soft tissue sarcoma: Japan Clinical Oncology Group Study JCOG1306. Jpn J Clin Oncol. 2014;44:765\u20139.","journal-title":"Jpn J Clin Oncol"},{"key":"1912_CR16","unstructured":"Fletcher, CDM, Bridge, JA, Hogendoorn, PCW, Mertens, F. WHO classification of tumours of soft tissue and bone. Lyon: International Agency for Research on Cancer; 2013."},{"key":"1912_CR17","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1200\/JCO.1997.15.1.350","volume":"15","author":"L Guillou","year":"1997","unstructured":"Guillou L, Coindre JM, Bonichon F, Nguyen BB, Terrier P, Collin F, et al. Comparative study of the National Cancer Institute and French Federation of Cancer Centers Sarcoma Group grading systems in a population of 410 adult patients with soft tissue sarcoma. J Clin Oncol. 1997;15:350\u201362.","journal-title":"J Clin Oncol."},{"key":"1912_CR18","unstructured":"Edge, SB, Byrd, DR, Compton, CC, Fritz AG, Greene FL, Trotti A, editors. AJCC cancer staging manual, 7th edition. Cham: Springer; 2011."},{"key":"1912_CR19","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228\u201347.","journal-title":"Eur J Cancer"},{"key":"1912_CR20","doi-asserted-by":"publisher","first-page":"163","DOI":"10.2307\/2530299","volume":"38","author":"DA Schoenfeld","year":"1982","unstructured":"Schoenfeld DA, Richter JR. Nomograms for calculating the number of patients needed for a clinical trial with survival as an endpoint. Biometrics. 1982;38:163\u201370.","journal-title":"Biometrics"},{"key":"1912_CR21","doi-asserted-by":"publisher","first-page":"659","DOI":"10.2307\/2336502","volume":"70","author":"KKG Lan","year":"1983","unstructured":"Lan KKG, DeMets DL. Discrete sequential boundaries for clinical trials. Biometrika. 1983;70:659\u201363.","journal-title":"Biometrika"},{"key":"1912_CR22","doi-asserted-by":"publisher","first-page":"1501","DOI":"10.1002\/sim.4780121516","volume":"12","author":"DJ Spiegelhalter","year":"1993","unstructured":"Spiegelhalter DJ, Freedman LS, Parmar MK. Applying Bayesian ideas in drug development and clinical trials. Stat Med. 1993;12:1501\u201311.","journal-title":"Stat Med."},{"key":"1912_CR23","doi-asserted-by":"publisher","first-page":"2178","DOI":"10.1200\/JCO.19.03289","volume":"38","author":"A Gronchi","year":"2020","unstructured":"Gronchi A, Palmerini E, Quagliuolo V, Martin Broto J, Lopez Pousa A, Grignani G, et al. Neoadjuvant chemotherapy in high-risk soft tissue sarcomas: final results of a randomized trial from Italian (ISG), Spanish (GEIS), French (FSG), and Polish (PSG) Sarcoma Groups. J Clin Oncol. 2020;38:2178\u201386.","journal-title":"J Clin Oncol."},{"key":"1912_CR24","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1016\/S1470-2045(16)00010-3","volume":"17","author":"D Callegaro","year":"2016","unstructured":"Callegaro D, Miceli R, Bonvalot S, Ferguson P, Strauss DC, Levy A, et al. Development and external validation of two nomograms to predict overall survival and occurrence of distant metastases in adults after surgical resection of localised soft-tissue sarcomas of the extremities: a retrospective analysis. Lancet Oncol. 2016;17:671\u201380.","journal-title":"Lancet Oncol"},{"key":"1912_CR25","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.ejca.2018.12.009","volume":"109","author":"S Pasquali","year":"2019","unstructured":"Pasquali S, Pizzamiglio S, Touati N, Litiere S, Marreaud S, Kasper B, et al. The impact of chemotherapy on survival of patients with extremity and trunk wall soft tissue sarcoma: revisiting the results of the EORTC-STBSG 62931 randomised trial. Eur J Cancer. 2019;109:51\u201360.","journal-title":"Eur J Cancer."},{"key":"1912_CR26","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1038\/nm.2174","volume":"16","author":"F Chibon","year":"2010","unstructured":"Chibon F, Lagarde P, Salas S, P\u00e9rot G, Brouste V, Tirode F, et al. Validated prediction of clinical outcome in sarcomas and multiple types of cancer on the basis of a gene expression signature related to genome complexity. Nat Med. 2010;16:781\u20137.","journal-title":"Nat Med."},{"key":"1912_CR27","doi-asserted-by":"publisher","first-page":"11078","DOI":"10.1200\/JCO.2019.37.15_suppl.TPS11078","volume":"37S","author":"A Italiano","year":"2019","unstructured":"Italiano A, Blay JY, Le Cesne A, Bompas E, Piperno-Neumann S, Duffaud F, et al. Benefit of intensified perioperative chemotherapy within high-risk CINSARC patients with resectable soft tissue sarcomas (CIRSARC). J Clin Oncol. 2019;37S:11078.","journal-title":"J Clin Oncol."},{"key":"1912_CR28","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1007\/s10147-013-0627-5","volume":"19","author":"T Takano","year":"2014","unstructured":"Takano T, Niikura H, Ito K, Nagase S, Utsunomiya H, Otsuki T, et al. Feasibility study of gemcitabine plus docetaxel in advanced or recurrent uterine leiomyosarcoma and undifferentiated endometrial sarcoma in Japan. Int J Clin Oncol. 2014;19:897\u2013905.","journal-title":"Int J Clin Oncol."},{"key":"1912_CR29","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1016\/S1470-2045(17)30622-8","volume":"18","author":"B Seddon","year":"2017","unstructured":"Seddon B, Strauss SJ, Whelan J, Leahy M, Woll PJ, Cowie F, et al. Gemcitabine and docetaxel versus doxorubicin as first-line treatment in previously untreated advanced unresectable or metastatic soft-tissue sarcomas (GeDDiS): a randomised controlled phase 3 trial. Lancet Oncol. 2017;18:1397\u2013410.","journal-title":"Lancet Oncol"},{"key":"1912_CR30","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-022-09195-y","volume":"22","author":"Y Oda","year":"2022","unstructured":"Oda Y, Tanaka K, Hirose T, Hasegawa T, Hiruta N, Hisaoka M, et al. Standardization of evaluation method and prognostic significance of histological response to preoperative chemotherapy in high-grade non-round cell soft tissue sarcomas. BMC Cancer. 2022;22:94.","journal-title":"BMC Cancer"},{"key":"1912_CR31","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1200\/JCO.2014.58.3781","volume":"33","author":"ML Hensley","year":"2015","unstructured":"Hensley ML, Miller A, O\u2019Malley DM, Mannel RS, Behbakht K, Bakkum-Gamez JN, et al. Randomized phase III trial of gemcitabine plus docetaxel plus bevacizumab or placebo as first-line treatment for metastatic uterine leiomyosarcoma: an NRG Oncology\/Gynecologic Oncology Group study. J Clin Oncol. 2015;33:1180\u20135.","journal-title":"J Clin Oncol."}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41416-022-01912-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41416-022-01912-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41416-022-01912-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,11]],"date-time":"2022-10-11T19:04:58Z","timestamp":1665515098000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41416-022-01912-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,23]]},"references-count":31,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2022,11,1]]}},"alternative-id":["1912"],"URL":"https:\/\/doi.org\/10.1038\/s41416-022-01912-5","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.742249872.793596116","asserted-by":"object"}]},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"value":"0007-0920","type":"print"},{"value":"1532-1827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,23]]},"assertion":[{"value":"28 April 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 June 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 June 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 July 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"KT received honoraria from Taiho Pharmaceutical, Eisai, and Novartis. AK received honoraria from Lilly, Taiho Pharmaceutical, Eisai, Novartis, and Otsuka Pharmaceutical. H Hiraga received honoraria from Taiho Pharmaceutical, Daiichi-Sankyo, and Novartis. YS received honoraria from Bayer AG, and a grant from LOXO Oncology. HF received honoraria from Chugai Pharmaceutical. The other authors declare that they have no conflicts of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"All patients provided written informed consent to participate in this study. The study was approved by each participating institution\u2019s Institutional Review Board. This study was performed in accordance with the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}